Why Is There Low Utilization of Biosimilars in Inflammatory Bowel Disease Patients by Gastroenterology Advanced Practice Providers?

AIM: To assess knowledge, practice patterns and attitudes toward the use of biosimilars by Advanced Practice Providers (APPs) treating patients with inflammatory bowel disease (IBD). BACKGROUND: APPs provide care in a variety of healthcare settings including medical specialties. In Gastroenterology,...

Descripción completa

Detalles Bibliográficos
Autores principales: Bernasko, Nana, Clarke, Kofi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Observations and Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802381/
https://www.ncbi.nlm.nih.gov/pubmed/36777276
http://dx.doi.org/10.1093/crocol/otab004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802381/
https://www.ncbi.nlm.nih.gov/pubmed/36777276
http://dx.doi.org/10.1093/crocol/otab004

Ejemplares similares